Editorial & Scientific Sourcing Policy
Peptides Agora is committed to independent, doctor-reviewed scientific journalism and regulatory reporting. Our mission is to provide accurate, evidence-based education regarding peptide pharmacology, clinical trials, and federal health policies.
1. Primary Evidence & Peer-Reviewed Sourcing
Every factual assertion regarding pharmacokinetics, therapeutic mechanisms, or safety outcomes must be substantiated by primary sources. Acceptable sources include:
- Peer-reviewed biomedical literature indexed in PubMed, MEDLINE, or EMBASE.
- Official regulatory dockets, transcripts, and briefing documents from the U.S. Food and Drug Administration (FDA), including Pharmacy Compounding Advisory Committee (PCAC) votes.
- Clinical trial registries and readouts from ClinicalTrials.gov and the World Health Organization (WHO).
- Official monographs from the United States Pharmacopeia (USP).
2. Complete Commercial Independence
Peptides Agora does not sell peptides, manufacture research compounds, or maintain affiliate partnerships with unverified peptide vendors or "research chemical" shops. Our editorial coverage is completely insulated from commercial interests. Any sponsored research summaries or directory listings are explicitly labeled.
3. Responsible Scientific Language
In compliance with YMYL medical publishing standards, our writers avoid unsubstantiated claims or sensationalism. We clearly distinguish between:
4. Corrections & Editorial Accountability
We promptly correct any factual inaccuracies. If a reader, researcher, or clinician identifies an error in our reporting, our editorial board investigates within 24 hours and appends a transparent correction note at the top of the article. Contact corrections at editor@peptidesagora.com.